Europe Companion Diagnostics Market By Technology (Immunohistochemistry, Polymerase chain reaction (PCR), Next generation sequencing (NGS), In Situ Hybridization, and Other Technology) By Indication (Oncology, Neurology and Other Indications) By Cancer Type, the Oncology market is segmented into Breast Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer and Other Cancer Type)

Chapter 1. Market Scope and Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Companion Diagnostics Market, by Technology
1.4.2 Europe Companion Diagnostics Market, by Indication
1.4.3 Europe Companion Diagnostics Market, by Cancer Type
1.4.4 Europe Companion Diagnostics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Executive Summary
2.1.3 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Companion Diagnostics Market by Technology
3.1 Europe Immunohistochemistry Market by Country
3.2 Europe Polymerase chain reaction (PCR) Market by Country
3.3 Europe Next generation sequencing (NGS) Market by Country
3.4 Europe In Situ Hybridization Market by Country
3.5 Europe Other Technology Market by Country
Chapter 4. Europe Companion Diagnostics Market by Indication
4.1 Europe Oncology Companion Diagnostics Market by Country
4.2 Europe Companion Diagnostics Market by Cancer Type
4.2.1 Europe Breast Cancer Companion Diagnostics by Country
4.2.2 Europe Colorectal Cancer Companion Diagnostics by Country
4.2.3 Europe Lung Cancer Companion Diagnostics by Country
4.2.4 Europe Blood Cancer Companion Diagnostics by Country
4.2.5 Europe Other Cancer Type Companion Diagnostics Market by Country
4.3 Europe Neurology Companion Diagnostics Market by Country
4.4 Europe Other Indications Companion Diagnostics Market by Country
Chapter 5. Europe Companion Diagnostics Market by Country
5.1 Germany Companion Diagnostics Market
5.1.1 Germany Companion Diagnostics Market by Technology
5.1.2 Germany Companion Diagnostics Market by Indication
5.1.2.1 Germany Companion Diagnostics Market by Cancer Type
5.2 UK Companion Diagnostics Market
5.2.1 UK Companion Diagnostics Market by Technology
5.2.2 UK Companion Diagnostics Market by Indication
5.2.2.1 UK Companion Diagnostics Market by Cancer Type
5.3 France Companion Diagnostics Market
5.3.1 France Companion Diagnostics Market by Technology
5.3.2 France Companion Diagnostics Market by Indication
5.3.2.1 France Companion Diagnostics Market by Cancer Type
5.4 Russia Companion Diagnostics Market
5.4.1 Russia Companion Diagnostics Market by Technology
5.4.2 Russia Companion Diagnostics Market by Indication
5.4.2.1 Russia Companion Diagnostics Market by Cancer Type
5.5 Spain Companion Diagnostics Market
5.5.1 Spain Companion Diagnostics Market by Technology
5.5.2 Spain Companion Diagnostics Market by Indication
5.5.2.1 Spain Companion Diagnostics Market by Cancer Type
5.6 Italy Companion Diagnostics Market
5.6.1 Italy Companion Diagnostics Market by Technology
5.6.2 Italy Companion Diagnostics Market by Indication
5.6.2.1 Italy Companion Diagnostics Market by Cancer Type
5.7 Rest of Europe Companion Diagnostics Market
5.7.1 Rest of Europe Companion Diagnostics Market by Technology
5.7.2 Rest of Europe Companion Diagnostics Market by Indication
5.7.2.1 Rest of Europe Companion Diagnostics Market by Cancer Type
Chapter 6. Company Profiles
6.1 Agilent Technologies, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research and Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Product launches:
6.1.5.2 Expansions:
6.2 Almac Group
6.2.1 Company Overview
6.2.1 Recent strategies and developments:
6.2.1.1 Collaborations, partnerships and agreements:
6.3 ARUP Laboratories, Inc.
6.3.1 Company Overview
6.4 Abbott Laboratories (Abbott Laboratories Molecular, Inc.)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research and Development Expense
6.5 Danaher Corporation
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research and Development Expense
6.5.5 Recent strategies and developments:
6.5.5.1 Acquisition and mergers:
6.6 Thermo Fischer Scientific, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research and Development Expense
6.6.5 Recent strategies and developments:
6.6.5.1 Collaborations, partnerships and agreements:
6.6.5.2 Expansions:
6.7 Hologic, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research and Development Expense
6.7.5 Recent strategies and developments:
6.7.5.1 Product launches:
6.7.5.2 Acquisition and mergers:
6.8 Novartis AG
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.8.4 Research and Development Expense
6.8.5 Recent strategies and developments:
6.8.5.1 Collaborations, partnerships and agreements:
6.9 Illumina, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research and Development Expense
6.9.5 Recent strategies and developments:
6.9.5.1 Product launches:
6.9.5.2 Acquisition and mergers:
6.9.5.3 Collaborations, partnerships and agreements:
6.1 Qiagen N.V.
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Regional Analysis
6.10.4 Research and Development Expense
6.10.5 Recent strategies and developments:
6.10.5.1 Product launches:
6.10.5.2 Collaborations, partnerships and agreements: